Depression
Conditions
Keywords
nonseasonal major depression disorder, light therapy
Brief summary
To compare the efficacy of blue light, bright light and dim light in the treatment of with nonseasonal major depression disorder(MDD) in adults.
Detailed description
The current study aims to compare the efficacy of blue light, bright light and dim light in the treatment of with nonseasonal major depression disorder(MDD) in adults. 162 patients with nonseasonal MDD will be randomized into three groups (i.e. blue light, bright light or dim light). The treatment will be performed five times a week for the first two weeks. And for the next 2 weeks, the treatment for patients will be undertook three times a week. There will be 16 times in total. The investigators will assess nonseasonal MDD'symptom severity in the baseline, 1 week,2 week, 4 week,6 week and 8 week. Through the study, 17-item Hamilton Depression Rating Scale (HAMD17),14-item Hamilton Anxiety Rating Scale (HAMA14),Quick Inventory of Depressive Symptoms, Self-Rated version (QIDS-SR)，Pittsburgh sleep quality index (PSQI) , Clinical Global Impression scale(CGI), Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q),Morningness-Eveningness Questionnaire (MEQ),Repeatable Battery for the Assessment of Neuropsychological Status(RBANS),subjective fatigue symptom scale and semantic differential scale will be obtained. The patients will also get individual's data of heart rate and blood pressure.
Interventions
DEVICEblue light
Patients receive exposure to 100lux blue light, which dominant wave-length is 468nm for 30 minutes in the morning.
DEVICEbright light
Patients receive exposure to 1000lux bright light, which dominant wave-length is 490nm for 30 minutes in the morning.
DEVICEdim light
Patients receive exposure to 100lux dim light, which dominant wave-length is 490nm for 30 minutes in the morning.
Sponsors
Shanghai Mental Health Center, Jingan District
Shanghai Mental Health Center, Yangpu District
Fudan University
Shanghai Zhongshan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* meet criteria for major depressive episodes as determined by MINI * HAMD17≥17 * received antidepressive medication at stable dosages for at least 14 days
Exclusion criteria
* Any axis I psychiatric disorder comorbidity * who have received formal psychological therapy, MECT or rTMS in 3 months * any current significant medical condition especially eye diseases * serious suicide risk * pregnant or breastfeeding women * depression with seasonal pattern * treatment-resistant depression * epilepsy in the past
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in 17-item Hamilton Depression Rating Scale (HAMD17) | from baseline to 8 weeks | It assesses the severity of depression symptom. The responder on HAMD17 is defined as a HAMD17 decrease at least 50% from the baseline at post-treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in 14-item Hamilton Anxiety Rating Scale (HAMA14) | from baseline to 8 weeks | It assesses the severity of anxiety symptom. |
| Change in Pittsburgh sleep quality index (PSQI) | from baseline to 8 weeks | It assesses the quality of sleep. |
| Change in Clinical Global Impression scale(CGI) | from baseline to 8 weeks | It gives an overall clinical impression to the continuous outcome measures. |
| Change in Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q) | from baseline to 8 weeks | It assesses the quality of life, enjoyment and satisfaction |
| Change in Quick Inventory of Depressive Symptoms, Self-Rated version (QIDS-SR) | from baseline to 8 weeks | It's a self-rated inventory which assesses the severity of depression symptom |
| Change in Repeatable Battery for the Assessment of Neuropsychological Status(RBANS) | from baseline to 8 weeks | It assesses cognitive function |
| Change in subjective fatigue symptom scale | from baseline to 8 weeks | It assesses subjective fatigue symptom related to the light therapy |
| Change in semantic differential scale | from baseline to 8 weeks | It assesses subjective feeling related to the light therapy |
| Change in Morningness-Eveningness Questionnaire (MEQ) | from baseline to 8 weeks | It assesses the circadian phase |
Contacts
Primary ContactYuan Wang, MD
Backup ContactXiao Huang, MD,PhD
Outcome results
None listed